Transcell Oncologics Launches Cell-based Platform Portfolio Partners With HAV Life Sciences For Distribution

Furthering its dedication to being creative biotech providing value to the preclinical research tools markets, Transcell Oncologics’s launched its cell-based platforms portfolio named Transtoxbio. It also announced HAV Life Sciences as its authorized channel/business partner in selected geographies. Transcell Oncologics is a portfolio company of Indian Angel Network.

With its robust portfolio of primary, progenitor cell-based platforms as predictive in-vitro tools accelerating drug and cosmetics preclinical exploratory research and testings applications demonstrated, Transtoxbio targets academics, contract research, pharma, cosmetics global markets. The applications are shown cover: Basic to Translational Research in Life Sciences; real-time prediction on biocompatibility, target (molecular, proteins), functional efficacy, and safety profiles of simple to complex molecules that are being investigated or developed as drug or cosmeceutical candidates.

Additionally, global cosmeceutical industry is constantly looking to improve their face value by introducing cruelty-free products into the markets; with Transtoxbio portfolio, if integrated at their R&D stage could turn to be disruptive and impactful in their delivery.

With this new partnership with HAV team, the targeted industry will continue to have more options to address their specific preclinical situation, requirement leveraging Transcell Oncologics’s progressive portfolio and HAV's network. Transcell is eager to penetrate deeper into new geographies offering its portfolio with HAV as one of the selected partners to help them unlock the value, applications in preclinical markets which is estimated to be 56.34 B$.

This partnership aligns with our core strategy on Transtoxbio portfolio and can help meet the portfolio’s financial goals and aspirations”, said S Dravida, Founder & CEO of Transcell group. “Transcell team is knowledgeable and has proven technical expertise in what they are offering through Transtoxbio portfolio, which should prove to be extremely valuable for clients who adopt alternative approaches in their preclinical R&D applications. This is precisely the foundation for our interest and pride in association representing them”, said Vikas Sadvilkar & Hetang Shah, Partners at HAV. With this inked relationship, HAV taps it’s established networks in India, European Union, East Asia markets adding value to the portfolio from their deliverables.